We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The CMA has accepted legally binding commitments from Essential Pharma to continue supplying a key bipolar drug at an affordable price for at least 5 years.
MHRA Chief Executive Dr June Raine explains the process behind the Agency's approval of the Pfizer/BioNTech vaccine
The first COVID-19 vaccine for the UK, developed by Pfizer/BioNTech, has today been given approval for use following a thorough review carried out by the Medicines and Healthcare products Regulatory Agency (MHRA).
The safety of the public will always come first.
The CMA is consulting on proposed commitments from Essential Pharma to keep a key bipolar drug on the market, and ensure it is affordable to the NHS.
Safety is our watch word.
Women using modafinil are being warned of an increased risk of birth defects associated with modafinil use during pregnancy.
First published during the 2019 to 2022 Johnson Conservative government
We are reviewing the risks and benefits of the acne medicine, isotretinoin. In particular whether some of the possible psychiatric and sexual side effects continue after treatment has been stopped.
The Yellow Card scheme is the UK’s system for reporting suspected side effects to medicines and adverse events with medical devices run by the Medicines and Healthcare products Regulatory Agency (MHRA).
Government announces restrictions on the export of supplies of flu vaccines to protect supplies for UK patients.
US-licensed flu vaccine (Flublok) to be used as part of the UK’s 2020/21 seasonal flu programme
The National Institute for Biological Standards and Control (NIBSC) will play a key role in evaluating vaccines that have been developed for COVID-19
New laws will allow more healthcare workers to administer flu and potential COVID-19 vaccines safely to the public.
The Medicines and Healthcare products Regulatory Agency (MHRA) is the latest regulator to join the Australia-Canada-Singapore-Switzerland (ACSS) Consortium.
The MHRA has published advice for patients and healthcare professionals
Stronger warnings about the risk of dependence and addiction to be added to the patient information leaflet and discussed with patients
The MHRA will now issue all safety-critical alerts for medicines and medical devices that require action as National Patient Safety Alerts
Reporting suspected side effects or incidents to the Yellow Card scheme supports the safe use of medical products for everyone
Stephen Lightfoot will become Chair of the Medicines and Healthcare products Regulatory Agency (MHRA) from 1 September 2020.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).